|
|
||||||||
Brief Research Reports |
Correspondence: 1Corresponding Author: Jose Joaquín Cerón, Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, University of Murcia, 30100 Espinardo Campus, Murcia, Spain. jjceron{at}um.es
| Abstract |
|---|
|
|
|---|
Key Words: Automated assay porcine serum total sialic acid validation
The acute-phase response refers to a nonspecific and complex reaction of an animal that occurs shortly after a tissue injury. The origin of this reaction can be attributable to infectious, immunologic, neoplastic, traumatic, or other causes, and its purpose is to restore homeostasis and to remove the cause of its disturbance. This response, among other systemic effects, includes the change in serum concentrations of the so-called acute-phase proteins (APP).11 Testing for these APPs is thought to be a suitable tool for monitoring the health and well-being of pigs.11 At the herd level, APP might be useful for determining in which part of the production system a disturbance is taking place,10 and it may also be applied to measure the efficacy of antibiotic treatment.9
Most APPs are glycoproteins that contain sialic acid.13 Sialic acid is a 9-carbon monosaccharide mainly attached to the oligosaccharide side-chains of many glycoprotein and glycolipids.13 In humans, it is known that serum-sialic-acid concentration rises during the acute-phase reaction, because of an increase in serum concentration of sialic-acid–carrying APPs, as well as a higher degree of sialylation of these proteins.2,13 Hence, sialic acid is considered an acute-phase marker in human medicine.1 The increase in APP in humans accounts for about 70% of circulating total sialic acid (TSA) concentrations during an acute-phase response. Thus, measuring TSA provides an integrated measure of the inflammatory response, which is less prone to day-to-day variability than individual markers. Based on this fact, it has been suggested that a single measurement of serum TSA may be the most useful estimate of an individual's habitual inflammatory status.1 In addition to this role as an inflammation marker, TSA levels have been found to increase in humans during various types of cancer, chronic renal failure, cardiovascular diseases, and diabetes.13 In veterinary medicine, several studies carried out on this marker in cattle, dogs, and horses during inflammatory or neoplastic disorders showed that sialic acid can be used as an acute-phase marker in these species.3,8,12,15,16 However, to the authors' knowledge, sialic acid has not been evaluated in swine as an acute-phase marker. The purpose of the current study was to evaluate the possible use of serum TSA as an acute-phase marker in pigs by the analytical validation of an automated commercially available method, as well as the estimation of the ability of the assay to differentiate between clinically healthy pigs and pigs with different diseases.
The study sample of animals consisted of 39 conventional Duroc x (Landrace x Large White) pigs from a finishing unit of 1,800 animals. The farm was seropositive to Porcine reproductive and respiratory syndrome virus (PRRSV), Porcine circovirus-2 (PCV-2), Mycoplasma hyopneumoniae, and Actinobacillus pleuropneumoniae. The herd vaccination program included vaccination twice against M. hyopneumoniae in the nursery (first week of age with revaccination 3 weeks after) and twice against Suid herpesvirus 1 (gE-negative modified live vaccine with oil in water adjuvant) at 11 and 14 weeks of age. Animals were introduced into the finishing unit with an average age of 190 days and an average weight of 102 kg. All animals in the present study were reared under the welfare conditions described in the European Union Council Directive 91/630/EEC, Council Directive 2001/88/EC, and Commission Directive 2001/93/EC, which detail minimum standards for the protection of pigs. Animals were classified, depending on their health status, into healthy and diseased animals.
The group of healthy animals was composed of 14 pigs from the same fattening unit destined for slaughter, aged 27 weeks, seronegative for PRRSV, PCV-2, M. hyopneumoniae, and A. pleuropneumoniae. These animals were determined to be healthy after a complete physical examination, which included evaluation of body condition, conformation, coat, behavior, posture and gait, abdominal shape, respiration (which included respiratory rate, rhythm, intensity, and type), appetite, and evidence of diarrhea, vomiting, coughing and/or sneezing, and temperature checking. They were transported to the slaughterhouse by following instructions from the European Union (European Directive 2001/88/CE). Transport and lairage never exceeded 3 hr. Animals were slaughtered by cutting the throat, after having been stunned in a chamber that contained carbon dioxide and were bled out with a Rotastick pump.a Blood samples were collected directly from the neck wound produced by the bleeding system by using a single-use blood collection system.b Blood was allowed to clot at room temperature and then was centrifuged at 1,000 x g for 10 min to obtain serum. All serum samples were kept at –20°C until analysis. After slaughter, postmortem and histologic examinations were carried out, and no lesions were found.
The group of diseased animals was composed of 25 pigs aged 27 weeks of age that exhibited various severe clinical signs (i.e., acute dyspnea, cough, fever, lameness, tail bites, and cachexia) and a pronounced weakness, which prohibited shipment to the abattoir; therefore, they were slaughtered at the farm. Blood samples were collected before slaughter by jugular venipuncture by using a single-use blood collection system.b Serum was obtained and preserved as described in the preceding paragraph. After slaughter, postmortem and histologic examinations were carried out. These examinations revealed that all 25 pigs had pulmonary lesions (suppurative/fibrinous bronchopneumonia, embolic/bronchointerstitial pneumonia, or chronic pleurisy), and that 13 of these animals also had other multiorgan lesions (ileitis, polyserositis, tail bites, or chronic arthritis).
The TSA concentrations were determined by using the sialic-acid test kit,c a colorimetric assay for enzymatic measurement of sialic acid in serum samples. The assay starts with the release of sialic-acid molecules bound to the sample glycoconjugates; this results in free sialic acid, which, after several enzymatic steps, is converted into a red chromophore. The absorbance of this chromophore is measured at 550 nm and is then related to the sample's original sialic-acid concentration, with a calibration curve established by using the standard serum included in the kit.
Because the sialic-acid kit was originally designed for manual use, it was necessary to adapt the assay to a Cobas Mira Plus Analyzer.d The adaptation was performed as previously described for canine serum samples,16 with slight modifications. Settings for the Cobas Mira Plus are summarized in Table 1. This automation has several advantages when compared with the manual method, such as higher throughput, use of a lower sample volume per determination, and a significant decrease in the volume of reagents used, which leads to a reduction in the cost of the test.4
|
Serum TSA concentrations from healthy and diseased animals described above were determined and compared. For clinical validation, all results were evaluated for normality of distribution by using a Kolmogorov–Smirnov test, and variance homogeneity was tested by a Levene test. When it was determined that the data did not follow a normal distribution (P < 0.001) and that there was no variance homogeneity (P < 0.001), then results were analyzed by the nonparametric Kruskal–Wallis test, and differences were considered significant when P < 0.05. All statistical computations were carried out by means of statistical software programs.f,g
Mean values, SDs, and precision results obtained in the analytical study are shown in Tables 2 and 3. The intra- and interassay CVs were lower than 6% and were similar to those reported in humans4,6 and dogs.16 The imprecision of this assay is lower than that of assays commercially available for the determination of other acute-phase markers in pigs, such as pig major acute protein, serum amyloid A, and C reactive protein, which ranged between 6.7% and 37.5% for the intra-assay CVs and between 9.5% and 39.4% for the interassay CVs.14 The main reason for these differences is that most of the assays used to determine APPs in pigs are manual enzyme-linked immunosorbent assays that involve manual sample dilution, which can be a source of imprecision.
|
|
|
|
| Sources and manufacturers |
|---|
|
|
|---|
b. Vacutainer®, BD SA, Madrid, Spain. ![]()
c. Roche Diagnostics GmbH, Mannheim, Germany. ![]()
d. Cobas Mira® Plus Analyzer, Horiba ABX, Montpellier, France. ![]()
e. International Union of Pure and Applied Chemistry (IUPAC) Compendium of Chemical Terminology (http://goldbook.iupac.org/L03540.html). ![]()
f. Microsoft® Excel, Microsoft Corp., Silicon Valley, CA. ![]()
g. SPSS software, version 11.5, SPSS Inc., Chicago, IL. ![]()
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |